Keratosis Pilaris is NOT a Reliable Marker of Insulin Resistance
Keratosis pilaris (KP) should not be used as a standalone screening tool for insulin resistance or diabetes, though its presence in the context of obesity and other risk factors warrants metabolic evaluation. While some association exists between KP and insulin resistance, the evidence is insufficient to establish it as a reliable diagnostic marker, and established clinical indicators like acanthosis nigricans are far more specific.
The Evidence on KP and Insulin Resistance
The relationship between KP and insulin resistance is weak and inconsistent:
- In a 2023 study of obese children, KP was among the top five dermatoses positively correlated with insulin resistance 1, and darker skin color increased the probability of KP (OR 0.306)
- A 2014 Spanish study found KP in 42% of obese patients, but unlike acanthosis nigricans and skin tags, KP showed no independent association with insulin levels in regression analysis 2
- A 1988 study of 13 patients with acanthosis nigricans and insulin resistance found 9 out of 13 had KP, but this was a highly selected population already diagnosed with insulin resistance 3
- A 2007 study in type 1 diabetic children found KP in 12% versus 1.5% of controls, and KP was associated with acquired ichthyosis but not with diabetes duration or metabolic control 4
The critical distinction: KP appears to be associated with obesity and possibly insulin resistance in some populations, but it lacks the specificity and independent correlation with insulin levels that would make it clinically useful for screening.
Established Markers of Insulin Resistance
The American Diabetes Association and American Heart Association guidelines clearly identify acanthosis nigricans as a sign of insulin resistance warranting screening, but KP is conspicuously absent from these recommendations 5, 6, 7, 8, 5.
Recognized clinical markers include:
- Acanthosis nigricans (dark, velvety skin in body folds)
- Skin tags (acrochordons)
- Obesity (BMI ≥85th percentile in children, ≥25 kg/m² in adults, ≥23 kg/m² in Asian Americans)
- Hypertension
- Dyslipidemia
- Polycystic ovary syndrome
When to Screen for Insulin Resistance/Diabetes
In Children and Adolescents
Screen if overweight/obese (≥85th percentile) PLUS one or more of 5, 7, 8:
- Maternal diabetes or gestational diabetes during pregnancy
- First- or second-degree relative with type 2 diabetes
- High-risk ethnicity (Native American, African American, Latino, Asian American, Pacific Islander)
- Acanthosis nigricans (not KP)
- Hypertension, dyslipidemia, or PCOS
- Small-for-gestational-age birth weight
Testing begins after puberty onset or age 10 years, whichever is earlier. Repeat every 3 years if normal, or more frequently if BMI increasing.
In Adults
Screen starting at age 35 years for all adults, or earlier if overweight/obese (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) PLUS one or more risk factors 7, 8:
- First-degree relative with diabetes
- High-risk ethnicity
- History of cardiovascular disease
- Hypertension (≥140/90 mmHg or on therapy)
- HDL <35 mg/dL or triglycerides >250 mg/dL
- PCOS
- Physical inactivity
- Acanthosis nigricans (not KP)
Screening Tests to Order
Use any of these three tests 5, 7, 5, 8, 5:
- Fasting plasma glucose: 100-125 mg/dL indicates prediabetes
- 2-hour plasma glucose during 75-g OGTT: 140-199 mg/dL indicates prediabetes
- Hemoglobin A1C: 5.7-6.4% indicates prediabetes
Repeat testing every 3 years if normal, or annually if prediabetes is detected.
Clinical Approach When KP is Present
If you encounter a patient with KP:
- Assess for obesity: Calculate BMI and determine if overweight/obese
- Look for acanthosis nigricans: Check neck, axillae, groin for dark, velvety patches
- Evaluate other risk factors: Family history, ethnicity, blood pressure, lipid abnormalities
- Screen for diabetes/prediabetes ONLY if the patient meets the established criteria above (obesity plus additional risk factors)
- Treat the KP itself with topical keratolytics (lactic acid, glycolic acid, urea, salicylic acid) and moisturizers 9, 10; Nd:YAG laser for refractory cases 10
Key Pitfall to Avoid
Do not order diabetes screening based solely on the presence of KP. This would lead to unnecessary testing in patients without established risk factors. KP is extremely common (affects up to 40% of adults), benign, and primarily a cosmetic concern 9, 11. The presence of KP in an obese patient with other risk factors may add to your clinical suspicion, but it should never be the sole trigger for metabolic screening.
The bottom line: Follow established ADA guidelines for diabetes screening based on obesity, family history, ethnicity, and the presence of acanthosis nigricans—not keratosis pilaris 5, 7, 8.